PSA Pharma: Otsuka Holdings (4578): Pricing Advantage
Analyst Pelham Smithers wonders just how much the market knows about the Jynarque pricing story and concludes that that it isn’t particularly well known.Otsuka Holdings is a pharmaceutical holding company. Co. operates in four business segments. Pharmaceutical segment is engaged in the sale of ethical pharmaceutical; the manufacture, sale and export of curative medicine; as well as the research and development of pharmaceutical products. Nutraceuticals segment manufactures, purchases and sells functional beverages and foods. Consumer Products segment manufactures and sells consumer products and mineral water. Others segment is involved in the manufacture and sale of chemical products; the manufacture, import and sale of measurement instrument; and the provision of transportation and warehousing services.
Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods.
PSA produces both company and sector reports. The focus of PSA’s research is to identify winners and losers as new technologies impact the top and bottom lines of corporations. Critical to our research is the clear explanation of how these new technologies work and how they impact companies and industries.
The founding partners have worked closely together for twenty years and the team has more than doubled in size since 2012.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.